Ruti Aga and the Six-Year Ban: Two Years for the Drug, Four for a Prescription No Clinic Ever Wrote

Let me start where the room went quiet.

The Athletics Integrity Unit's statement landed in the inbox on a Thursday afternoon. Two paragraphs. No press conference, no camera bank, no hand raised to ask what had actually happened. A former Tokyo Marathon champion received a six-year ban and not one hard question was asked about it in any sports room that day. That silence is the loudest thing in the file — because the day an Indian sprinter breaks a national record there are forty cameras, and the day a former Major champion's career ends there is an email.

In January 2026 I was standing in the finish-line interview pit at the Mumbai Marathon. Forty-one short interviews in six hours, most of them with women running their first 10K. I learned something that day that keeps returning to every script: the question is never the split. The question is who paid for the spikes. In Ruti Aga's case that question shifts slightly — who wrote the name on the prescription, and did that person have the right to write it.

Context: the athlete who never lost on the track lost on paper

Ruti Aga is an Ethiopian marathoner, thirty-two years old. Her career is not the kind that gets counted in headlines, but anyone who watches road running seriously knows where the name sits. She won the Tokyo Marathon in 2026. A year earlier she was second in Berlin, running somewhere around two hours eighteen in that era, a Major runner-up. Three second-place finishes at World Marathon Majors in all. This is the tier of athlete who does not break world records but whose name appears in the top five of every big race.

In March she won a half marathon in China. A sample collected after that race came back positive. The statement says she had been provisionally suspended since 10 September, and the decision issued on Thursday set a total ban of six years. The real question is not whether six years is too much or too little. The real question is how those six broke down — two and four.

Consider the economy of the Chinese label-race circuit. For East African marathoners these races are the easiest and most profitable part of the year. Places in the Majors are scarce, a body can absorb only two or three marathons a season, but a half marathon is manageable and the appearance fee is decent. This is the income layer that keeps a household running. It is also now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races, and the collision is not a coincidence.

Core: the substance was misclassified, and that is the whole case

First, the technical error that travelled with this story worldwide. Reports called methylprednisolone a "prohibited steroid" and said WADA classifies it as performance enhancing. That is wrong. Methylprednisolone is a glucocorticoid — class S9 on the WADA Prohibited List, not an anabolic steroid under S1. And under the current List, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes.

One sentence and the entire case turns over. A therapeutic knee injection given out of competition is entirely legal. It becomes a violation only if residues are present in-competition. So the finding rested not on the drug but on route and timing. A road race's testing window opens at 23:59 the day before the race, which means an injection given days earlier can still be caught. That is not a technicality. That is the point on which a defence could have been built.

An old habit returns here. In 2026, when the country was locked down and the national camp at Patiala had shut, I made thirty-four calls to women athletes. My first question was never "what is your target." It was: who pays your rent. In Ruti Aga's case the same question takes another form — who writes your treatment, and does that person hold a registration.

That is where the real story begins. Aga cited a knee injury, and intra-articular methylprednisolone for knee synovitis in distance runners is standard sports-medicine practice. The explanation is medically plausible. Which is exactly why the prescription that was submitted became fatal. If the treatment had genuinely happened and the records were real, those records would have been the defence. But what was submitted was not a record.

According to the statement, the "doctor" who wrote the prescription was a family member with no medical registration. The clinic named on the prescription did not exist. When asked, the person claimed to have used an old prescription pad from a former workplace — a pad the clinic explicitly disowned. Three independent verification failures: no clinic, no registration, no pad. Three separate links breaking in one forgery is rare. Usually one weak link survives.

Then the detail that rarely makes headlines: the four-year tampering sanction did not come from a document alone. It came from an interview — from statements made under questioning. That matters. It means the athlete was asked questions, answers were recorded, and the answers did not match the paperwork. The AIU's interview conditions with Ethiopian athletes, particularly on language and translation, have been a recurring point of contention, and this case does not settle that argument. But when three independent verifications fail, the translation defence weakens considerably.

The arithmetic: two plus four, and the message buried inside

Six years is not a novel sanction. It is standard Code arithmetic. Two years for the presence violation — consistent with a specified substance finding where intent is not proven. Four years for tampering — the Code's default. Two plus four, six.

But the sum carries a message. If the panel had found no significant fault, the presence sanction could have dropped to a reprimand or a substantially reduced period. That the total stopped at two plus four means the panel declined that relief. There is also a near-paradox worth noting: forged documentation is itself circumstantial evidence of concealment intent, yet it did not escalate the presence sanction further. The panel weighed the two on separate scales.

The backdating to 10 September is not a discount. Provisional suspension time counts against a ban, so in real terms the athlete gains nothing. That is procedural housekeeping, not relief. And note what the statement does not say: the scope of disqualification. Standard AIU practice is automatic annulment of the competition where the sample was collected, so the March result and its prize money are very likely void. But what is not written cannot be reported as fact. I will not put an inference where a fact belongs.

Contrarian: this is not a doping case, it is a document case

Here is where I think the story is being read wrongly.

On social media it is circulating as "runner caught on steroids." That comparison fails twice. First, methylprednisolone has no proven endurance benefit. It reduces inflammation, dulls pain, and puts a runner on a start line her knee should have kept her off. That is medicine, not enhancement — and that distinction is precisely what separates S9 from S1. Second, filing this in the queue of anabolic cases casts doubt over an entire record that was actually about paperwork. Three Major runner-up finishes and the 2026 Tokyo title belong to a period in which no violation was established — and because this case is anchored to a later race, earlier results are not automatically annulled. The unsanctioned should not be shadowed. That discipline is the same one the 2026 cases taught: name the sanctioned, date them exactly, and leave everyone else clean in the copy.

Now the harder paradox. Six years for a substance with no proven endurance benefit, imposed on the population with the thinnest medical infrastructure. Two readings will follow, and both will be legitimate. On one side, this is evidence of AIU rigour, because what was caught here was not a drug but a lie. On the other, it is evidence of inequity, because if this athlete had held a credentialed team physician, a file, a TUE application, there may have been no case at all. The sanction punished not the medicine but the decision taken after the resources ran out.

My own country's experience is instructive here, and I offer it as comparison, not prescription. In India a Railways-quota athlete has a department that signs leave for a camp, a team doctor, a file. East African road running has no such department. There is an agent, a camp, and the rest is the athlete's own pocket and contacts. The medical file becomes a private liability — and when there is no means to carry that liability, a person manufactures a prescription. That is not an excuse. It is a causal chain.

There is another silence that needs naming. The AIU statement mentions only the family member. It does not say who the agent was, which management company was involved, where the camp coach stood, or why the Ethiopian federation issued no statement at all. When a thirty-two-year-old athlete takes the biggest decisions of her life alone, the question should not be asked only of her. It should also be asked of the structure that left her alone.

The plain arithmetic of age

A six-year ban at thirty-two means a return at thirty-eight. Ethiopian women's marathon depth is such that a two-hour-eighteen runner is not guaranteed a national team place. A thirty-eight-year-old returning with a doping record is not a selection question at all. In that sense the ban is technically six years and functionally a lifetime.

And one thing must be said plainly, even though it stings. Her career did not end at the race she won in March. It ended in the interview where she gave an answer that did not match a document. Had that same knee injection been given at the right time, by the right route, with a filed record, we would be writing about something else entirely. What ended this career was not the knee and not the drug. It was the prescription.

Forward

The change that matters after this case will not be in a press release. It will be whether the next East African runner who needs a knee injection has a phone number her agent can call. The next fight in anti-doping is not over samples. It is over documents — a real clinic, a real registration, a real date. If that structure is not built, the next case will look the same: small drug, large lie, six years.

The question is not whether Ruti Aga deserved a sanction. The question is why a sport that let her win in Tokyo went quiet on the day her name was in large type for the last time.